Edgewise Therapeutics Inc [EWTX] stock is trading at $15.53, up 11.81%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EWTX shares have gain 5.86% over the last week, with a monthly amount glided 12.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on July 30, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $46. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 30, 2025, and set its price target to $42. On April 30, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $41 on the stock. Scotiabank downgraded its rating to a Sector Perform but stick to its price target of $14 on April 02, 2025. Scotiabank initiated its recommendation with a Sector Outperform and recommended $50 as its price target on March 07, 2025. Stifel started tracking with a Hold rating for this stock on January 22, 2025, and assigned it a price target of $30. In a note dated November 22, 2024, Evercore ISI initiated an Outperform rating and provided a target price of $45 on this stock.
Edgewise Therapeutics Inc [EWTX] stock has fluctuated between $10.60 and $38.12 over the past year. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $15.53 at the most recent close of the market. An investor can expect a potential return of 202.64% based on the average EWTX price forecast.
Analyzing the EWTX fundamentals
Gross Profit Margin for this corporation currently stands at -1.11% with Operating Profit Margin at -82.41%, Pretax Profit Margin comes in at -71.15%, and Net Profit Margin reading is -71.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.31 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Edgewise Therapeutics Inc’s Current Ratio is 28.87. In addition, the Quick Ratio stands at 28.87 and the Cash Ratio stands at 2.08.
Transactions by insiders
Recent insider trading involved Russell Alan J, Chief Scientific Officer, that happened on Aug 26 ’25 when 100000.0 shares were sold. Officer, ALAN J RUSSELL completed a deal on Aug 26 ’25 to buy 100000.0 shares. Meanwhile, General Counsel MOORE JOHN R sold 2098.0 shares on Aug 12 ’25.
